Nirvana Life Sciences Inc.
NIRVF
$0.083
$0.0830.00%
OTC PK
| 01/31/2025 | 10/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 7.84% | 12.40% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.84% | 12.40% | |||
| Operating Income | -7.84% | -12.40% | |||
| Income Before Tax | -23.83% | -9.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -23.83% | -9.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 0.00% | 100.00% | |||
| Net Income | -23.66% | -9.54% | |||
| EBIT | -7.84% | -12.40% | |||
| EBITDA | -8.80% | -13.64% | |||
| EPS Basic | -23.66% | -9.41% | |||
| Normalized Basic EPS | -24.14% | -9.43% | |||
| EPS Diluted | -23.66% | -9.41% | |||
| Normalized Diluted EPS | -24.14% | -9.43% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||